FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308394688> ?p ?o ?g. }

• W4308394688 abstract "<h3>Background</h3> Checkpoint inhibitors (CPIs) targeting PD-1/PD-L1 and CTLA-4 have dramatically improved outcomes for a range of solid malignancies. irAEs from CPIs affect a wide range of tissues, vary in severity, and are difficult to predict. Multiple studies have reported on incidence of irAEs by immunotherapy type, but few have examined the association of irAEs with tumor histology or with sites of metastasis. This study aims to investigate the association between type and incidence of irAEs with type of solid tumor histology, as well as with sites of cancer metastasis. <h3>Methods</h3> We performed a retrospective analysis of all patients with genitourinary (GU), melanoma, gastrointestinal (GI), and lung malignancies treated with CPI monotherapy at the University of California, Irvine using an outpatient oncology pharmacy database. Data was collected from 1/1/2020 to 6/30/2021. Patients were aged 18 years and older. Patients must have received at least one dose of a CPI agent. Patients who received CPI-containing combination therapy with chemotherapy or targeted therapy were excluded. <h3>Results</h3> Of 423 patients on unique treatment lines in our data set, 268 patients received CPI monotherapy. irAEs were documented in 133 patients (49.6%). 71 patients (62.8%) required treatment with oral or intravenous steroids, and 42 patients (37.2%) received treatment with other supportive therapy. The incidence of irAEs based on tumor type is listed in table 1. Most common irAEs per tumor type were rash in GU malignancies (26.0%), colitis in melanoma (25.4%), rash in GI malignancies (29.3%), and pneumonitis in lung malignancies (60.0%). In patients with irAEs, 102 (76.7%) had metastatic disease and of those, 18 (17.6%) had an irAE involving a metastatic site (p<0.0001). In patients with irAEs involving the primary site of malignancy, 2 patients (4.7%) with renal cell carcinoma had nephritis, 12 patients (37.5%) with melanoma had dermatitis, and 2 patients (50%) with a lung malignancy had pneumonitis. <h3>Conclusions</h3> This study examines the differences in type and incidence of irAEs across GU, melanoma, GI, and lung cancers treated with CPI monotherapy. We found differences in the incidence of irAEs as relavant to tumor histology. Further, there was a statistically significant increased incidence of irAEs involving a metastatic site. Additional studies are needed, including those with a larger sample, combination immunotherapy and chemotherapy, as well as with additional tumor histologies. <h3>Ethics Approval</h3> Application #16536 for HS #2021-6843 titled, ”Primary Cancer Histology and Sites of Metastatic Disease Correlate with Tissues Affected by Immune-Related Adverse Events” obtained approval by the University of California, Irvine Institutional Review Board. A waiver of consent was obtained as this study involved no more than minimal risk as it was a retrospective chart review." @default.
• W4308394688 created "2022-11-11" @default.
• W4308394688 creator A5015026946 @default.
• W4308394688 creator A5015734050 @default.
• W4308394688 creator A5031407490 @default.
• W4308394688 creator A5034198986 @default.
• W4308394688 creator A5037349480 @default.
• W4308394688 creator A5067357021 @default.
• W4308394688 date "2022-11-01" @default.
• W4308394688 modified "2023-09-23" @default.
• W4308394688 title "1247 Distribution of immune-related adverse events (irAEs) in solid malignancies" @default.
• W4308394688 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1247" @default.
• W4308394688 hasPublicationYear "2022" @default.
• W4308394688 type Work @default.
• W4308394688 citedByCount "0" @default.
• W4308394688 crossrefType "proceedings-article" @default.
• W4308394688 hasAuthorship W4308394688A5015026946 @default.
• W4308394688 hasAuthorship W4308394688A5015734050 @default.
• W4308394688 hasAuthorship W4308394688A5031407490 @default.
• W4308394688 hasAuthorship W4308394688A5034198986 @default.
• W4308394688 hasAuthorship W4308394688A5037349480 @default.
• W4308394688 hasAuthorship W4308394688A5067357021 @default.
• W4308394688 hasBestOaLocation W43083946881 @default.
• W4308394688 hasConcept C120665830 @default.
• W4308394688 hasConcept C121332964 @default.
• W4308394688 hasConcept C121608353 @default.
• W4308394688 hasConcept C126322002 @default.
• W4308394688 hasConcept C143998085 @default.
• W4308394688 hasConcept C167135981 @default.
• W4308394688 hasConcept C197934379 @default.
• W4308394688 hasConcept C2777658100 @default.
• W4308394688 hasConcept C2778570526 @default.
• W4308394688 hasConcept C502942594 @default.
• W4308394688 hasConcept C61511704 @default.
• W4308394688 hasConcept C71924100 @default.
• W4308394688 hasConceptScore W4308394688C120665830 @default.
• W4308394688 hasConceptScore W4308394688C121332964 @default.
• W4308394688 hasConceptScore W4308394688C121608353 @default.
• W4308394688 hasConceptScore W4308394688C126322002 @default.
• W4308394688 hasConceptScore W4308394688C143998085 @default.
• W4308394688 hasConceptScore W4308394688C167135981 @default.
• W4308394688 hasConceptScore W4308394688C197934379 @default.
• W4308394688 hasConceptScore W4308394688C2777658100 @default.
• W4308394688 hasConceptScore W4308394688C2778570526 @default.
• W4308394688 hasConceptScore W4308394688C502942594 @default.
• W4308394688 hasConceptScore W4308394688C61511704 @default.
• W4308394688 hasConceptScore W4308394688C71924100 @default.
• W4308394688 hasLocation W43083946881 @default.
• W4308394688 hasOpenAccess W4308394688 @default.
• W4308394688 hasPrimaryLocation W43083946881 @default.
• W4308394688 hasRelatedWork W1969276543 @default.
• W4308394688 hasRelatedWork W1970383787 @default.
• W4308394688 hasRelatedWork W2066797670 @default.
• W4308394688 hasRelatedWork W2275480158 @default.
• W4308394688 hasRelatedWork W2409957712 @default.
• W4308394688 hasRelatedWork W2981372661 @default.
• W4308394688 hasRelatedWork W3095306390 @default.
• W4308394688 hasRelatedWork W3154734119 @default.
• W4308394688 hasRelatedWork W4238089809 @default.
• W4308394688 hasRelatedWork W4241346791 @default.
• W4308394688 isParatext "false" @default.
• W4308394688 isRetracted "false" @default.
• W4308394688 workType "article" @default.